Cargando…

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells

BACKGROUND: Abelson (ABL) tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML); however, many patients develop resistance during ABL TKI therapy. Vitamin K2 (VK2) is a crucial fat-soluble vitamin used to activate hepatic coagulation factors and treat osteoporosis. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okabe, Seiichi, Gotoh, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478393/ https://www.ncbi.nlm.nih.gov/pubmed/37670241 http://dx.doi.org/10.1186/s12885-023-11304-4

Ejemplares similares

P661: EFFECT OF VITAMIN K2 ON COVID-19 S1 PROTEIN-INDUCED CYTOTOXICITY AGAINST HUVECS AND ON THE ACTION OF ASCIMINIB IN ABELSON-TYROSINE-KINASE-INHIBITOR-RESISTANT CHRONIC MYELOGENOUS LEUKEMIA CELLS
por: Okabe, Seiichi, et al.
Publicado: (2023)

Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells
por: Okabe, Seiichi, et al.
Publicado: (2015)

Refractory pancytopenia upon initiation of asciminib in tyrosine kinase inhibitor-resistant chronic myeloid leukemia
por: Tessier, Steven, et al.
Publicado: (2023)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells
por: Honma, Yoshio, et al.
Publicado: (1990)

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib
por: G. Lindström, H. Jonathan, et al.
Publicado: (2020)

The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor–Treated Chronic Myelogenous Leukemia
por: Lavoie, Declan C T, et al.
Publicado: (2019)

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021)

Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells
por: Mitrovský, Ondřej, et al.
Publicado: (2023)

PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS
por: Breccia, M., et al.
Publicado: (2022)

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib
por: Tomassetti, Sarah, et al.
Publicado: (2022)

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia
por: Lei, Hu, et al.
Publicado: (2021)

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective
por: Ghosh, K
Publicado: (2022)

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
por: Ono, Takaaki
Publicado: (2021)

A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors
por: Li, Qing, et al.
Publicado: (2016)

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
por: Hochhaus, Andreas, et al.
Publicado: (2023)

P681: MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA
por: Atallah, Ehab, et al.
Publicado: (2023)

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
por: Atallah, Ehab, et al.
Publicado: (2023)

Myelomastocytic Blast Cell Crisis in Resistant Tyrosine Kinase Inhibitor Chronic Myelogenous Leukemia: Case Report and Review of Literature
por: Martinez-Cordero, Humberto, et al.
Publicado: (2019)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
por: Pérez-Lamas, Lucía, et al.
Publicado: (2023)

Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
por: Okumura, Lucas M., et al.
Publicado: (2015)

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
por: Hirao, Takuya, et al.
Publicado: (2017)

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: A single center experience
por: Bommannan, KB, et al.
Publicado: (2022)

Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
por: Padala, Sandeep, et al.
Publicado: (2023)

The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors
por: Tesileanu, C Mircea S, et al.
Publicado: (2023)

Dysregulated Dscam levels act through Abelson tyrosine kinase to enlarge presynaptic arbors
por: Sterne, Gabriella R, et al.
Publicado: (2015)

Extramedullary Involvement by Chronic Myelogeneous Leukemia in Five Patients With Unusual Clinicopathologic Features: A Review of the Effectiveness of Tyrosine Kinase Inhibitors
por: Soni, Abha, et al.
Publicado: (2016)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Prevalence of Abelson murine leukemia viral oncogene homolog-breakpoint cluster region fusions and correlation with peripheral blood parameters in chronic myelogenous leukemia patients in Lorestan Province, Iran
por: Kiani, Ali Asghar, et al.
Publicado: (2016)

Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
por: Choi, Eun-Ji
Publicado: (2023)

Asciminib in chronic myeloid leukemia: many questions still remain to be answered
por: Eşkazan, Ahmet Emre
Publicado: (2021)

Abelson tyrosine-protein kinase 2 regulates myoblast proliferation and controls muscle fiber length
por: Lee, Jennifer K, et al.
Publicado: (2017)

Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients
por: Rivera, Donna R, et al.
Publicado: (2020)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
por: Martinelli, Giovanni, et al.
Publicado: (2009)

Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment
por: Tanaka, Yuko, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study
por: Katagiri, Seiichiro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mqa72jqiu1dbbbkpf46sgbveqb